vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Turning Point Brands, Inc. (TPB). Click either name above to swap in a different company.

Turning Point Brands, Inc. is the larger business by last-quarter revenue ($121.0M vs $77.6M, roughly 1.6× Bioceres Crop Solutions Corp.). Turning Point Brands, Inc. runs the higher net margin — 6.8% vs -9.6%, a 16.4% gap on every dollar of revenue. On growth, Turning Point Brands, Inc. posted the faster year-over-year revenue change (29.2% vs -16.8%). Over the past eight quarters, Turning Point Brands, Inc.'s revenue compounded faster (20.7% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Turning Point Australia (TPAUS) is a conservative lobby group based in Australia, affiliated with Turning Point USA but independent of it. Founded by Joel Jammal and first registered in 2023, the group has become active in trying to influence the outcome of the 2026 South Australian state election in March 2026.

BIOX vs TPB — Head-to-Head

Bigger by revenue
TPB
TPB
1.6× larger
TPB
$121.0M
$77.6M
BIOX
Growing faster (revenue YoY)
TPB
TPB
+46.0% gap
TPB
29.2%
-16.8%
BIOX
Higher net margin
TPB
TPB
16.4% more per $
TPB
6.8%
-9.6%
BIOX
Faster 2-yr revenue CAGR
TPB
TPB
Annualised
TPB
20.7%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
TPB
TPB
Revenue
$77.6M
$121.0M
Net Profit
$-7.4M
$8.2M
Gross Margin
46.8%
55.9%
Operating Margin
9.3%
16.5%
Net Margin
-9.6%
6.8%
Revenue YoY
-16.8%
29.2%
Net Profit YoY
-20.2%
239.8%
EPS (diluted)
$-0.12
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
TPB
TPB
Q4 25
$121.0M
Q3 25
$77.6M
$119.0M
Q2 25
$116.6M
Q1 25
$60.6M
$106.4M
Q4 24
$98.8M
$93.7M
Q3 24
$93.3M
$90.7M
Q2 24
$93.2M
Q1 24
$84.0M
$83.1M
Net Profit
BIOX
BIOX
TPB
TPB
Q4 25
$8.2M
Q3 25
$-7.4M
$21.1M
Q2 25
$14.5M
Q1 25
$-1.6M
$14.4M
Q4 24
$605.2K
$2.4M
Q3 24
$-6.2M
$12.4M
Q2 24
$13.0M
Q1 24
$9.8M
$12.0M
Gross Margin
BIOX
BIOX
TPB
TPB
Q4 25
55.9%
Q3 25
46.8%
59.2%
Q2 25
57.1%
Q1 25
39.4%
56.0%
Q4 24
42.0%
56.0%
Q3 24
40.2%
55.6%
Q2 24
54.1%
Q1 24
50.8%
58.2%
Operating Margin
BIOX
BIOX
TPB
TPB
Q4 25
16.5%
Q3 25
9.3%
21.8%
Q2 25
22.6%
Q1 25
1.5%
21.8%
Q4 24
14.5%
19.1%
Q3 24
2.5%
22.9%
Q2 24
24.5%
Q1 24
15.7%
23.2%
Net Margin
BIOX
BIOX
TPB
TPB
Q4 25
6.8%
Q3 25
-9.6%
17.7%
Q2 25
12.4%
Q1 25
-2.6%
13.5%
Q4 24
0.6%
2.6%
Q3 24
-6.6%
13.6%
Q2 24
14.0%
Q1 24
11.6%
14.5%
EPS (diluted)
BIOX
BIOX
TPB
TPB
Q4 25
$0.40
Q3 25
$-0.12
$1.13
Q2 25
$0.79
Q1 25
$-0.02
$0.79
Q4 24
$0.00
$0.15
Q3 24
$-0.10
$0.68
Q2 24
$0.68
Q1 24
$0.14
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
TPB
TPB
Cash + ST InvestmentsLiquidity on hand
$15.5M
$222.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$372.0M
Total Assets
$734.9M
$763.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
TPB
TPB
Q4 25
$222.8M
Q3 25
$15.5M
$201.2M
Q2 25
$109.9M
Q1 25
$38.5M
$99.6M
Q4 24
$29.2M
$48.9M
Q3 24
$32.3M
$33.6M
Q2 24
$142.2M
Q1 24
$16.4M
$130.9M
Stockholders' Equity
BIOX
BIOX
TPB
TPB
Q4 25
$372.0M
Q3 25
$288.3M
$358.2M
Q2 25
$224.8M
Q1 25
$345.0M
$203.4M
Q4 24
$346.3M
$190.4M
Q3 24
$346.0M
$185.7M
Q2 24
$172.8M
Q1 24
$348.5M
$160.0M
Total Assets
BIOX
BIOX
TPB
TPB
Q4 25
$763.8M
Q3 25
$734.9M
$742.8M
Q2 25
$595.8M
Q1 25
$798.2M
$564.6M
Q4 24
$835.2M
$493.4M
Q3 24
$827.3M
$488.0M
Q2 24
$591.6M
Q1 24
$836.1M
$586.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
TPB
TPB
Operating Cash FlowLast quarter
$14.4M
$24.9M
Free Cash FlowOCF − Capex
$21.5M
FCF MarginFCF / Revenue
17.8%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
3.03×
TTM Free Cash FlowTrailing 4 quarters
$43.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
TPB
TPB
Q4 25
$24.9M
Q3 25
$14.4M
$3.3M
Q2 25
$11.8M
Q1 25
$23.3M
$17.4M
Q4 24
$-5.4M
$17.7M
Q3 24
$5.2M
$13.2M
Q2 24
$13.4M
Q1 24
$-17.4M
$22.6M
Free Cash Flow
BIOX
BIOX
TPB
TPB
Q4 25
$21.5M
Q3 25
$-721.0K
Q2 25
$7.8M
Q1 25
$15.2M
Q4 24
$16.6M
Q3 24
$12.6M
Q2 24
$10.9M
Q1 24
$22.3M
FCF Margin
BIOX
BIOX
TPB
TPB
Q4 25
17.8%
Q3 25
-0.6%
Q2 25
6.7%
Q1 25
14.3%
Q4 24
17.8%
Q3 24
13.9%
Q2 24
11.7%
Q1 24
26.8%
Capex Intensity
BIOX
BIOX
TPB
TPB
Q4 25
2.8%
Q3 25
3.4%
Q2 25
3.4%
Q1 25
2.1%
Q4 24
1.2%
Q3 24
0.7%
Q2 24
2.7%
Q1 24
0.4%
Cash Conversion
BIOX
BIOX
TPB
TPB
Q4 25
3.03×
Q3 25
0.16×
Q2 25
0.82×
Q1 25
1.21×
Q4 24
-8.85×
7.34×
Q3 24
1.07×
Q2 24
1.03×
Q1 24
-1.78×
1.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

TPB
TPB

US$111.5M92%
Non Us$9.6M8%

Related Comparisons